CA2139000A1 - Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+) - Google Patents

Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+)

Info

Publication number
CA2139000A1
CA2139000A1 CA002139000A CA2139000A CA2139000A1 CA 2139000 A1 CA2139000 A1 CA 2139000A1 CA 002139000 A CA002139000 A CA 002139000A CA 2139000 A CA2139000 A CA 2139000A CA 2139000 A1 CA2139000 A1 CA 2139000A1
Authority
CA
Canada
Prior art keywords
sibutramine
amount
pharmaceutically acceptable
human
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002139000A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2139000A1 publication Critical patent/CA2139000A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002139000A 1992-06-23 1993-06-22 Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+) Abandoned CA2139000A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90303492A 1992-06-23 1992-06-23
US903,034 1992-06-23

Publications (1)

Publication Number Publication Date
CA2139000A1 true CA2139000A1 (fr) 1994-01-06

Family

ID=25416828

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002139000A Abandoned CA2139000A1 (fr) 1992-06-23 1993-06-22 Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+)

Country Status (5)

Country Link
EP (1) EP0708639A4 (fr)
JP (1) JPH07508281A (fr)
AU (1) AU4542993A (fr)
CA (1) CA2139000A1 (fr)
WO (1) WO1994000047A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
AU773490B2 (en) * 1999-03-19 2004-05-27 Abbott Gmbh & Co. Kg Treatment of osteoarthritis
CZ20013607A3 (cs) * 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
JP4220243B2 (ja) 2001-02-12 2009-02-04 ワイス Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
WO2002083631A1 (fr) 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
GB2098601B (en) * 1981-04-02 1985-07-24 Sandoz Products Ltd Improvements in or relating to organic compounds
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤

Also Published As

Publication number Publication date
EP0708639A1 (fr) 1996-05-01
JPH07508281A (ja) 1995-09-14
AU4542993A (en) 1994-01-24
WO1994000047A1 (fr) 1994-01-06
EP0708639A4 (fr) 1997-08-20

Similar Documents

Publication Publication Date Title
CA2138998A1 (fr) Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (-)
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
CA2139000A1 (fr) Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (+)
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US5648396A (en) Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
EP1904066B1 (fr) COMBINAISONS D'ESZOPICLONE ET DE TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTALENAMINE, pour le TRAITEMENT DE LA MENOPAUSE, perimenopause ET des TROUBLES COGNITIFS
US20030078303A1 (en) Methods of treating and preventing sexual dysfunction using (+) sibutramine in combination with phosphodiesterase inhibitors
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JPH03294248A (ja) Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物
EP0687472A2 (fr) Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
US4690949A (en) Therapeutic drug for dementia
CA2318960A1 (fr) Utilisations pharmaceutiques de (+)-bupropion optiquement pur
JP2004501130A (ja) ５−ｈｔ３受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての１−アミノ−アルキルシクロヘキサン
US20020006963A1 (en) Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5492933A (en) Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
WO1992013452A1 (fr) Procedes d'utilisation et compositions de r(-) fluoxetine
WO1995010270A1 (fr) Procedes de traitement de l'incontinence urinaire a l'aide de terodiline optiquement pure

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050622